Vanderbilt Study Reveals Fat vs. Muscle Loss Tradeoff with Semaglutide and Tirzepatide
Research in JAMA Network Open shows semaglutide, tirzepatide, and bariatric surgery all produce substantial fat mass reduction but also cause reductions in lean mass over 24 months, highlighting the body composition tradeoff in GLP-1 treatment.